Results 111 to 120 of about 2,713,581 (258)

Liquid biopsy‐based diagnostic evaluation of hypermethylated CpG sites for ovarian cancer diagnosis

Molecular Oncology, EarlyView.
This schematic outlines the workflow from biomarker identification to duplex MethyLight assay validation for epithelial ovarian cancer diagnosis using cfDNA‐based liquid biopsy. Initial screening of hypermethylated CpG candidates (cg02957270, cg10061138 cg00480298, COL2A1) was performed in tissue using ARMS‐PCR, COBRA, qPCR and image analysis. Selected
Deepa Bisht, Sameer Gupta, Amrita Chaurasia, Manisha Sachan   +3 more
wiley   +1 more source

Epigenetic heterogeneity and plasticity in therapy‐induced tumor states through single‐cell multi‐omics

Molecular Oncology, EarlyView.
Single‐cell multi‐omics reveals epigenetic heterogeneity across therapy‐adaptive tumor states, including quiescent/dormant, drug‐tolerant persister, and EMT‐like phenotypes. By linking regulatory features with state‐associated biomarkers, these approaches inform biomarker‐guided therapeutic strategies for evolving tumors.
Hee Jung Kim, Hwiyeong Lee, Jin Hong, Daechan Park   +3 more
wiley   +1 more source

Utilization of Netnography as a Health Care Research Methodology: Scoping Review. [PDF]

J Med Internet Res
Sadat A, Green E, Forsythe I, Munnelly S, Eaton G, Wynn M, Pearson F, Dobson E.   +7 more
europepmc   +1 more source

Vignette Research Methodology: An Essential Tool for Quality Improvement Collaboratives. [PDF]

Healthcare (Basel), 2022
Payton KSE, Gould JB.
europepmc   +1 more source

Inhibition of cyclin‐dependent kinases 12/13 using CT7439 as a treatment for colorectal cancer with CDK12 upregulation

Molecular Oncology, EarlyView.
The proposed mechanism of action for the CDK12/13 inhibitor and cyclin K degrader, CT7439. CDK12/13 inhibition interrupts transcription elongation, leading to increased DNA damage that results in cell death. This agent is a potentially novel treatment option for patients with colorectal cancer. Created in BioRender. Cyclin‐dependent kinase (CDK) 12 and
Wylie K. Watlington, Divya L. Dayanidhi, Mohammad Zokaasadi, John B. Mantyh, Pelumi D. Olawuni, Gabrielle Rupprecht, Jeremy M. Force, Shannon McCall, Ashwani K. Bahl, David S. Hsu, Jason A. Somarelli   +10 more
wiley   +1 more source

Tłı̨chǫ nàowoò hoghàseètǫǫ: learning a strong like two research methodology through the exploration of community-centered curation practices. [PDF]

AlterNative (Nga Pae Maramatanga (Organ))
Bourgeois RL.
europepmc   +1 more source

Building a Low-Cost Wireless Biofeedback Solution: Applying Design Science Research Methodology. [PDF]

Sensors (Basel), 2023
Cheng CF, Lin CJ.
europepmc   +1 more source

In vitro and in silico modelling of ROS1‐positive non‐small cell lung cancer reveals fusion‐dependent tyrosine kinase inhibitor responses

Molecular Oncology, EarlyView.
Drug resistance limits treatment success in a subset of lung cancers driven by ROS1 gene alterations. Using patient‐derived cells and computer simulations, we studied three key mutations and how they affect five targeted drugs. The mutations reduced drug effectiveness in different ways by altering protein structure and behavior.
Farhan Ul Haq, Marc Terrones, Felicia Rodrigues Fortes, Anne Schepers, Alessia Denis, Christophe Deben, Ken Op de Beeck, Guy Van Camp, Geert Vandeweyer   +8 more
wiley   +1 more source

Indigenous women's health and data sovereignty: imagining an Indigenous research methodology using quantitative methods. [PDF]

AlterNative (Nga Pae Maramatanga (Organ))
Crosschild C, Varcoe C, Brown HJ, Browne AJ.   +3 more
europepmc   +1 more source

The Art of Teaching Professional Practice: An Action Research Methodology Inspired by Ulrich's Systems Concepts. [PDF]

Syst Pract Action Res, 2023
van der Linde S, Goede R.
europepmc   +1 more source